Event-Driven Stocks

Theravance Biopharma, Inc.

TBPHNasdaq

Healthcare · Pharmaceutical Preparations · CA · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 2 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$15.4M$14.5M$10.4M$13.2M$14.3M$71.9M
Operating income−$14.4M−$11.2M−$24.9M−$38.5M−$83.9M−$297.6M
Net income−$13.6M−$11.7M−$22.1M−$25.9M−$79.7M−$278.0M
Total assets$485.6M$354.2M$382.0M$607.4M$374.8M$469.1M
Total liabilities——————
Equity$296.7M$175.5M$213.0M$441.8M−$338.6M−$303.8M
EPS (diluted)$-0.27$-0.24$-0.35$-0.34$-1.24$-4.46
Shares out.49.5M48.2M62.9M74.7M64.3M62.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−93.8%
Net margin
−88.2%
Return on equity
−4.6%
Return on assets
−2.8%
Return on capital (ROCE)
−3.2%
Liabilities / assets
—
Debt / equity
—
Book value / share
$6.00
Revenue growth (YoY)
6.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−51.9%clean
Piotroski F-Score
4/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
73
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 warning● 3 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20265.0M14.8-3.2%
Apr 30, 20265.2M14.1-0.8%
Apr 15, 20265.2M12.5-1.1%
Mar 31, 20265.3M7.8+2.2%
Mar 13, 20265.1M4.1+8.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)